Ernexa Therapeutics Appoints Dr. Robert J. Spiegel to Board
Ernexa Therapeutics has appointed Robert J. Spiegel, M.D., FACP, to its Board of Directors. The company is targeting an IND for ERNA-101 in Q4 2026 and a first-in-human study in Q1 2027.
Ernexa Therapeutics has appointed Robert J. Spiegel, M.D., FACP, to its Board of Directors. The company is targeting an IND for ERNA-101 in Q4 2026 and a first-in-human study in Q1 2027.